Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2025 | γ9δ2 T-cell activation with ICT01 and azacitidine-venetoclax in patients with newly diagnosed AML

Abhishek Maiti • 10 Sep 2025
SOHO 2025
Acute Myeloid Leukemia Leukemia Azacitidine ICT01 Venetoclax

In this video, Abhishek Maiti, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares the findings from a Phase I/II study investigating ICT01, a novel immunotherapy that activates γ9δ2 T-cells, in combination with azacitidine and venetoclax in patients with newly diagnosed acute myeloid leukemia (AML). This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Abhishek Maiti

ADVENT-AML trial: azacitidine, venetoclax, and allogeneic NK cells in R/R AML
3:52
ADVENT-AML trial: azacitidine, venetoclax, and allogeneic NK cells in R/R AML
Abhishek Maiti • 9 Sep 2025
Rationale for 10-day decitabine with venetoclax for high-risk AML
2:16
Rationale for 10-day decitabine with venetoclax for high-risk AML
Abhishek Maiti • 1 Jun 2020
Venetoclax with decitabine for high-risk AML and MDS
2:05
Venetoclax with decitabine for high-risk AML and MDS
Abhishek Maiti • 2 Jun 2020
Comparing outcomes of 10-day decitabine with venetoclax vs. chemotherapy in AML based on fitness
9:17
Comparing outcomes of 10-day decitabine with venetoclax vs. chemotherapy in AML based on fitness
Abhishek Maiti • 2 Jun 2020

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals